AbbVie Inc. is 152.7x more valuable than SUPERNUS PHARMACEUTICALS, INC. by market capitalization ($399.47 B vs $2.62 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | SUPN | ABBV |
|---|---|---|
| Market cap | $2.62 B | $399.47 B |
| US-listed rank | #1910 | #28 |
| Revenue (latest FY) | $718.95M | $61.16B |
| Net income (latest FY) | -$38.60M | $4.23B |
| Net margin | -5.4% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 1,154 | 1,008 |
AbbVie Inc. is 152.7x more valuable than SUPERNUS PHARMACEUTICALS, INC. by market capitalization ($399.47 B vs $2.62 B).
In their latest fiscal years, SUPERNUS PHARMACEUTICALS, INC. reported $718.95M in revenue while AbbVie Inc. reported $61.16B.
Full pages: SUPERNUS PHARMACEUTICALS, INC. and AbbVie Inc., or browse the full rankings.